Lilly's abemaciclib readout won't stop Phase III trial

The Phase III MONARCH 2 study of breast cancer candidate abemaciclib ( LY2835219) from Eli Lilly and Co. (NYSE:LLY) will continue after efficacy criteria were not met in a preplanned interim analysis, the company said.

The study is evaluating abemaciclib in combination with Faslodex fulvestrant to treat hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after first-line endocrine therapy. AstraZeneca plc (LSE:AZN; NYSE:AZN) markets Faslodex. ...